Clinical trials: Vascular And Immunologic Diseases
Type 1 Diabetes, Hypertension
Study of 24 Hour Blood Pressure and the Association to Complications to Type 1 Diabetes
The aim of the study is to evaluate the prevalence of abnormal nocturnal blood pressure (BP) in patients with type 1 diabetes. The investigators wish to gain knowledge on the relation between central and peripheral 24 hour BP and…
- Trial name
- PROFIL (NCT01171248)
- Where
- Denmark
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Steno Diabetes Center Copenhagen
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
The purpose if this study is to evaluate the side effects of the combination of bortezomib and Revlimid (CC-5013) in patients with relapsed and relapsed/refractory multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Multiple Myeloma
- Trial name
- NCT00153933
- Testing
- Bortezomib, CC-5013
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- Dana-Farber Cancer Institute
Refractory Multiple Myeloma, Stage II Multiple Myeloma
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
RATIONALE: Giving chemotherapy drugs, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00217438
- Testing
- melphalan, amifostine trihydrate, peripheral blood stem cell transplantation
- Where
- 4 sites in United States
- Volunteers
- 130 people
- Sponsor
- Fred Hutchinson Cancer Center
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients
The purpose of this study is to compare the effect of short-term (2 hours/120 minutes) and long-term (6 hours/360 minutes) schedules of crushed ice therapy (cryotherapy).
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01653106
- Testing
- cryotherapy, questionnaire administration, pharmacological study
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Chronic Spontaneous Urticaria
A Study of Single Dose of LP-003 in Healthy Adult Subjects
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy subjects.
- Trial name
- NCT06604949
- Testing
- LP-003 200mg
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Longbio Pharma
Relapsed and Refractory Multiple Myeloma
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
- Trial name
- NCT04155749
- Testing
- anitocabtagene-autoleucel
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kite, A Gilead Company
Relapsed or Refractory Multiple Myeloma
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
The investigators will perform a phase I/II trial of Revlimid daily for 21 days and Abraxane weekly for 3 weeks. Accrual will be on standard cohorts of 3 patients.
- Trial name
- rev/abraxane (NCT02075021)
- Testing
- Lenalidomide, nab-paclitaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NYU Langone Health
Multiple Myeloma
First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone
The purpose of this study was to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and early efficacy signs of M3258 as a single agent and co-administered with dexamethasone in participants with Relapsed…
- Trial name
- NCT04075721
- Testing
- M3258, M3258 20 mg
- Where
- 7 sites in United States, France
- Volunteers
- 10 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
ANCA Associated Vasculitis, Drug Use
Effect of Tofacitinib in Treating ANCA-associated Vasculitis
The goal of this study is to evaluate the efficacy and safety of tofacitinib 5 mg twice daily in AAV patients.
- Conditions
- ANCA Associated Vasculitis, Drug Use, JAK-STAT Pathway Deregulation
- Trial name
- NCT04973033
- Testing
- Tofacitinib
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Zhongshan Hospital
Stroke, Upper Extremity Paresis
Functional Recovery in Stroke Patients With Task-Specific Robot-Aided Arm Therapy
The goal of this study is to determine whether task-oriented, robot-aided therapy is more effective than conventional physical and occupational therapy at promoting functional recovery of the affected arm in chronic hemiparetic…
- Trial name
- NCT00719433
- Testing
- robot therapy (ARMin), conventional therapy
- Where
- Switzerland
- Volunteers
- 76 people
- Sponsor
- University of Zurich
Mitochondrial Diseases, Drug Resistant Epilepsy
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase.
- Conditions
- Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome
- Trial name
- MIT-E (NCT04378075)
- Testing
- Vatiquinone
- Where
- 27 sites in United States, Canada and 7 more
- Volunteers
- 68 people
- Sponsor
- PTC Therapeutics
Relapse/Refractory Multiple Myeloma
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
This is an open-label, single-arm study of ATG-010 (selinexor) plus low-dose Dexamethasone (Sd) in patients with multiple myeloma previously treated with lenalidomide and bortezomib refractory to prior treatment with…
- Trial name
- MARCH (NCT03944057)
- Testing
- ATG-010
- Where
- 17 sites in China
- Volunteers
- 82 people
- Sponsor
- Antengene Corporation
Chronic Urticaria, Idiopathic, Hidradenitis
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
The study duration for an individual subject includes screening (14 days), the treatment period (28 days) and the observational follow-up period of 28 days, in total 70 days ± 6 days.
- Conditions
- Chronic Urticaria, Idiopathic, Hidradenitis, Hidradenitis Suppurativa
- Trial name
- NCT06555328
- Testing
- CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment
- Where
- 29 sites in United States, Bulgaria and 4 more
- Volunteers
- 73 people
- Sponsor
- InflaRx GmbH
Stroke, Parkinson Disease
Videofluoroscopic Swallowing Study (VFSS)
The study procedure of simultaneous VFSS and DDS measurement will be completed in one day and the subject will be followed within 2 business days after the study procedure to monitor for adverse events.
- Conditions
- Stroke, Parkinson Disease, Multiple Sclerosis, Oropharyngeal Dysphagia
- Trial name
- PORSCHE (NCT03387267)
- Testing
- Dysphagia Detection System
- Where
- 13 sites in United States, Finland
- Volunteers
- 452 people
- Sponsor
- Société des Produits Nestlé (SPN)
Systemic Lupus Erythematosus, Insulin Resistance
Insulin Resistance and Atherosclerosis in Women With Lupus
This study will test the effects of insulin resistance on atherosclerosis (hardening of the arteries) in women who have systemic lupus erythematosus, more commonly known as lupus.
- Conditions
- Systemic Lupus Erythematosus, Insulin Resistance, Atherosclerosis
- Trial name
- NCT00544102
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Ebola Virus Disease, Marburg Virus Disease
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
Primary Objective: To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults.
- Trial name
- NCT04723602
- Testing
- cAd3-Marburg, cAd3-EBO-S
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Purpura, Schoenlein-Henoch
Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura
Due to high incidence of renal damage by Hench-schonlein Purpura(HSP) is the key to affect prognosis, this project moves the research emphasis forward in line with the idea of "prevention of progress of disease", Which concerns…
- Trial name
- NCT01104428
- Testing
- "ziying" granules
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Liaoning University of Traditional Chinese Medicine
Non Hodgkin Lymphoma, Multiple Myeloma
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial.
- Conditions
- Non Hodgkin Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03436771
- Testing
- JCAR017, JCARH125
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Influenza, Multiple Myeloma
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients
The investigators' hypothesis is that the administration of Fluzone® High-Dose with booster to all patients with monoclonal gammopathies (irrespective of age) will lead to seroconversion rates exceeding 50% and more importantly…
- Conditions
- Influenza, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Plasma Cell Disorders
- Trial name
- SHIVERING 2 (NCT02566265)
- Testing
- Fluzone High Dose Vaccine
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Yale University
Cancer
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
RATIONALE: Giving itraconazole or fluconazole may be effective in preventing infections in patients undergoing peripheral stem cell or bone marrow transplantation.
- Trial name
- NCT00003883
- Testing
- fluconazole, itraconazole
- Where
- 2 sites in United States
- Volunteers
- 578 people
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.